AMPK

Assets acting on this target.

Class
Biguanide (insulin sensitizer)
Notes
original target text: AMPK pathway

AMP-activated protein kinase (AMPK) is an enzyme that functions as the cell's principal sensor of energy status. It is activated when the ratio of AMP and ADP to ATP rises, a signal that cellular energy reserves are becoming depleted. Once active, AMPK shifts cellular metabolism toward energy conservation: it promotes glucose uptake and fatty acid oxidation while suppressing energy-consuming processes such as fatty acid, cholesterol, and glycogen synthesis. Because insulin resistance and type 2 diabetes are characterized by excess hepatic glucose production and impaired peripheral glucose disposal, pharmacologically engaging this pathway offers a way to correct metabolic imbalance without directly stimulating insulin secretion. Biguanides, a small-molecule drug class, work through this axis to lower blood glucose primarily by reducing glucose output from the liver. Beyond diabetes, AMPK signaling intersects with pathways relevant to obesity, polycystic ovary syndrome, and cellular aging, since it links nutrient availability to broader programs of growth, autophagy, and metabolic regulation. Modulating AMPK is therefore of interest wherever cells or tissues need to be redirected from energy expenditure and biosynthesis toward conservation and catabolism, making it a mechanism with relevance extending beyond glycemic control alone.

By indication

Related mechanisms

AMPK drugs compared

2 drugs, stage by indication
2 drugs acting on AMPK: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
metforminGlucophageNot recordedsmall moleculeApprovedApproved in Type 2 Diabetes
Retagliptin/metformin (Ruilintang)RuilintangJiangsu Hengrui Pharmaceuticalssmall molecule combinationPhase 1Phase 1 in Type 2 Diabetes

← all mechanisms